The present invention relates to a nasal delivery device for and a method of delivering substances, in particular one of a liquid, as a suspension or solution, or a powder, containing a medicament, especially systemic or topical pharmaceuticals, or a vaccine, to the nasal airway of a subject.
Referring to
There are many nasal conditions which require treatment. One such condition is nasal inflammation, specifically rhinitis, which can be allergic or non-allergic and is often associated with infection and prevents normal nasal function. By way of example, allergic and non-allergic inflammation of the nasal airway can typically effect between 10 and 20% of the population, with nasal congestion of the erectile tissues of the nasal concha, lacrimation, secretion of watery mucus, sneezing and itching being the most common symptoms. As will be understood, nasal congestion impedes nasal breathing and promotes oral breathing, leading to snoring and sleep disturbance. Other nasal conditions include nasal polyps which arise from the paranasal sinuses, hypertrophic adenoids, secretory otitis media, sinus disease and reduced olfaction.
In the treatment of certain nasal conditions, the topical administration of medicaments is preferable, particularly where the nasal mucosa is the prime pathological pathway, such as in treating or relieving nasal congestion. Medicaments that are commonly topically delivered include decongestants, anti-histamines, cromoglycates, steroids and antibiotics. At present, among the known anti-inflammatory pharmaceuticals, topical steroids have been shown to have an effect on nasal congestion. Topical decongestants have also been suggested for use in relieving nasal congestion. The treatment of hypertrophic adenoids and chronic secretory otitis media using topical decongestants, steroids and anti-microbial agents, although somewhat controversial, has also been proposed. Further, the topical administration of pharmaceuticals has been used to treat or at least relieve symptoms of inflammation in the anterior region of the nasopharynx, the paranasal sinuses and the auditory tubes.
Medicaments can also be systemically delivered through the nasal pathway, the nasal pathway offering a good administration route for the systemic delivery of pharmaceuticals, such as hormones, for example, oxytocin and calcitonin, and analgetics, such as anti-migraine compositions, as the high blood flow and large surface area of the nasal mucosa advantageously provides for rapid systemic uptake.
Nasal delivery is also expected to be advantageous for the administration of medicaments requiring a rapid onset of action, for example, analgetics, anti-emetics, insulin, anti-epileptics, sedatives and hypnotica, and also other pharmaceuticals, for example, cardio-vascular drugs. It is envisaged that nasal administration will provide for a fast onset of action, at a rate similar to that of injection and at a rate much faster than that of oral administration. Indeed, for the treatment of many acute conditions, nasal administration is advantageous over oral administration, since gastric stasis can further slow the onset of action following oral administration.
It is also expected that nasal delivery could provide an effective delivery route for the administration of proteins and peptides as produced by modern biotechnological techniques. For such substances, the metabolism in the intestines and the first-pass-effect in the liver represent significant obstacles for reliable and cost-efficient delivery.
Furthermore, it is expected that nasal delivery using the nasal delivery technique of the present invention will prove effective in the treatment of many common neurological diseases, such as Alzheimer's, Parkinson's, psychiatric diseases and intracerebral infections, where not possible using existing techniques. The nasal delivery technique of the present invention allows for delivery to the olfactory region, which region is located in the superior region of the nasal cavities and represents the only region where it is possible to circumvent the blood-to-brain barrier (BBB) and enable communication with the cerebrospinal fluid (CSF) and the brain.
Also, it is expected that the nasal delivery technique of the present invention will allow for the effective delivery of vaccines.
Aside from the delivery of medicaments, the irrigation of the nasal mucosa with liquids, in particular saline solutions, is commonly practised to remove particles and secretions, as well as to improve the mucociliary activity of the nasal mucosa. These solutions can be used in combination with active pharmaceuticals.
For any kind of drug delivery, accurate and reliable dosing is essential, but it is of particular importance in relation to the administration of potent drugs which have a narrow therapeutic window, drugs with potentially serious adverse effects and drugs for the treatment of serious and life-threatening conditions. For some conditions, it is essential to individualize the dosage to the particular situation, for example, in the case of diabetes mellitus. For diabetes, and, indeed, for many other conditions, the dosage of the pharmaceutical is preferably based on actual real-time measurements.
Currently, blood samples are most frequently used, but the analysis of molecules in the exhalation breath of subjects has been proposed as an alternative to blood analysis for several conditions. Breath analysis is currently used for the diagnosis of conditions such as helicobacter pylori infections which cause gastric ulcers.
WO-A-2000/051672 discloses a delivery device for delivering a substance, in particular a medicament, in a bi-directional flow through the nasal cavities, that is, an air flow which passes into one nostril, around the posterior margin of the nasal septum and in the opposite direction out of the other nostril. This bi-directional air flow advantageously acts to stimulate the sensory nerves in the nasal mucosa, thereby conditioning the subject for the delivery and providing a more comfortable delivery situation.
It is an aim of the present invention to provide nasal delivery devices and methods for delivering substances to a nasal cavity of subject, and in particular relatively-simple mechanically-actuatable delivery devices.
In one aspect the present invention provides a nasal delivery device for delivering substance to a nasal cavity of a subject, the delivery device comprising: a housing; a nosepiece for fitting to a nasal cavity of a subject; a mouthpiece through which the subject in use exhales; and a substance supply unit, which includes an actuation member which extends from one end of the housing and is manually actuated to deliver substance to the nasal cavity of the subject; wherein the housing includes a main body section, from one, base end of which extends the actuation member of the substance supply unit, and a grip section, which is disposed at the one end of the main body section, the grip section comprising a first, distal part which includes at least one projecting grip element by which the subject grips the housing in actuating the actuation member of the substance supply unit, and a second, proximal part which provides a recess in which fingers of the subject are located, whereby the recess promotes proper orientation of the delivery device in a hand of the subject.
In one embodiment the main body section comprises an elongate section.
In one embodiment the at least one projecting grip element is a circumferential lip which extends around or substantially around the periphery of the housing.
In another embodiment the distal part of the grip section comprises first and second projecting grip elements, which project to opposite sides of the housing, with no intermediate elements.
In one embodiment the first and second projecting grip elements are aligned on an axis common with that of the mouthpiece.
In another aspect the present invention provides a method of delivering substance to a nasal cavity of a subject, the method comprising the steps of: providing a nasal delivery device, comprising: a housing; a nosepiece for fitting to a nasal cavity of the subject; a mouthpiece through which the subject exhales; and a substance supply unit, which includes an actuation member which extends from one end of the housing and is manually actuated to deliver substance to the nasal cavity of the subject; wherein the housing includes a main body section, from one, base end of which extends the actuation member of the substance supply unit, and a grip section, which is disposed at the one end of the main body section, the grip section comprising a first, distal part which includes at least one projecting grip element by which the subject grips the housing in actuating the actuation member of the substance supply unit, and a second, proximal part which provides a recess in which fingers of the subject are located; fitting the nosepiece to the nasal cavity of the subject; locating the mouthpiece in the mouth of the subject; and gripping the housing such that fingers of the subject are located in the recess to opposite sides of the housing and adjacent the at least one projecting grip part, thereby promoting proper orientation of the delivery device in a hand of the subject to effect operation of the delivery device.
In one embodiment the main body section comprises an elongate section.
In one embodiment the at least one projecting grip element is a circumferential lip which extends around or substantially around the periphery of the housing.
In another embodiment the distal part of the grip section comprises first and second projecting grip elements, which project to opposite sides of the housing, with no intermediate elements.
In one embodiment the first and second projecting grip elements are aligned on an axis common with that of the mouthpiece.
Preferred embodiments of the present invention will now be described hereinbelow by way of example only with reference to the accompanying drawings, in which:
The delivery device comprises a housing 15, a nosepiece 17 for fitting in a nasal cavity of a subject, a mouthpiece 19 through which the subject in use exhales, and a substance supply unit 21, which includes an actuation member 23 which extends from one end of the housing 15 and is manually actuated to deliver substance to the nasal cavity of the subject.
The housing 15 includes a main body section 25, in this embodiment an elongate section, from one, base end of which extends the actuation member 23 of the substance supply unit 21.
The housing 15 further includes a grip section 27, which is disposed at the one end of the main body section 25.
The grip section 27 comprises a first, distal part 28 which includes at least one projecting grip element 29 by which a user grips the housing 15, typically between fingers, in actuating the actuation member 23 of the substance supply unit 21, and a second, proximal part 31 which provides a recess or waist 33 in which the fingers of the user are located.
In this embodiment the projecting grip element 29 is a circumferential flange or lip which extends around or substantially around the periphery of the housing 15.
The present inventors have recognized that the provision of the recess or waist 33 adjacent the flange or lip element 29 promotes proper orientation of the delivery device in the hand of the user, insofar as a user is required to orient the delivery device in a particular manner in the nasal cavity, in order to achieve optimal performance from the delivery device.
The delivery device of this embodiment is very similar to the above-described first embodiment, and thus, in order to avoid unnecessary duplication of description, only the differences will be described in detail.
In this embodiment the distal part 28 of the grip section 27 comprises first and second projecting grip elements 29a, 29b, which project to opposite sides of the housing 15, with no intermediate elements. In this embodiment the first and second projecting grip elements 29a, 29b are aligned on an axis common with that of the mouthpiece 19.
The present inventors have recognized that this configuration promotes a proper rotational orientation of the delivery device when gripped in the hand of a user, insofar as a user is required to orient the delivery device in a particular manner in the nasal cavity, in order to achieve optimal performance from the delivery device.
Finally, it will be understood that the present invention has been described in its preferred embodiments and can be modified in many different ways without departing from the scope of the invention as defined by the appended claims.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2013/053748 | 2/25/2013 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2013/124493 | 8/29/2013 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
605436 | Kellogg | Jun 1898 | A |
642748 | Manners | Feb 1900 | A |
746749 | Seidel | Dec 1903 | A |
5797392 | Keldmann et al. | Aug 1998 | A |
6648848 | Keldmann et al. | Nov 2003 | B1 |
6715485 | Djupesland | Apr 2004 | B1 |
D530815 | Murphy et al. | Oct 2006 | S |
7347201 | Djupesland | Mar 2008 | B2 |
7377901 | Djupesland et al. | May 2008 | B2 |
7481218 | Djupesland | Jan 2009 | B2 |
7543581 | Djupesland | Jun 2009 | B2 |
7740014 | Djupesland | Jun 2010 | B2 |
7784460 | Djupesland et al. | Aug 2010 | B2 |
7841337 | Djupesland | Nov 2010 | B2 |
7854227 | Djupesland | Dec 2010 | B2 |
7934503 | Djupesland et al. | May 2011 | B2 |
7975690 | Djupesland | Jun 2011 | B2 |
8047202 | Djupesland | Nov 2011 | B2 |
8146589 | Djupesland | Apr 2012 | B2 |
8171929 | Djupesland et al. | May 2012 | B2 |
8327844 | Djupesland | Dec 2012 | B2 |
8511303 | Djupesland | Aug 2013 | B2 |
8522778 | Djupesland | Sep 2013 | B2 |
8550073 | Djupesland | Oct 2013 | B2 |
8555877 | Djupesland | Oct 2013 | B2 |
8555878 | Djupesland | Oct 2013 | B2 |
8590530 | Djupesland et al. | Nov 2013 | B2 |
8596278 | Djupesland | Dec 2013 | B2 |
8800555 | Djupesland | Aug 2014 | B2 |
8875704 | Djupesland et al. | Nov 2014 | B2 |
8899229 | Djupesland et al. | Dec 2014 | B2 |
8910629 | Djupesland et al. | Dec 2014 | B2 |
D723156 | Djupesland et al. | Feb 2015 | S |
D725769 | Djupesland et al. | Mar 2015 | S |
8978647 | Djupesland et al. | Mar 2015 | B2 |
9010325 | Djupesland et al. | Apr 2015 | B2 |
9038630 | Djupesland et al. | May 2015 | B2 |
9067034 | Djupesland et al. | Jun 2015 | B2 |
9072857 | Djupesland | Jul 2015 | B2 |
9108015 | Djupesland | Aug 2015 | B2 |
9119932 | Djupesland | Sep 2015 | B2 |
9132249 | Djupesland | Sep 2015 | B2 |
9144652 | Djupesland et al. | Sep 2015 | B2 |
9168341 | Djupesland | Oct 2015 | B2 |
9205208 | Djupesland | Dec 2015 | B2 |
9205209 | Djupesland | Dec 2015 | B2 |
9272104 | Djupesland | Mar 2016 | B2 |
20020046751 | MacRae | Apr 2002 | A1 |
20040024330 | Djupesland et al. | Feb 2004 | A1 |
20040112378 | Djupesland | Jun 2004 | A1 |
20040112379 | Djupesland | Jun 2004 | A1 |
20040112380 | Djupesland | Jun 2004 | A1 |
20040149289 | Djupesland | Aug 2004 | A1 |
20040182388 | Djupesland | Sep 2004 | A1 |
20050028812 | Djupesland | Feb 2005 | A1 |
20050072430 | Djupesland | Apr 2005 | A1 |
20050235992 | Djupesland | Oct 2005 | A1 |
20060096589 | Djupesland | May 2006 | A1 |
20060107957 | Djupesland | May 2006 | A1 |
20060169278 | Djupesland et al. | Aug 2006 | A1 |
20060219240 | Djupesland | Oct 2006 | A1 |
20060219241 | Djupesland | Oct 2006 | A1 |
20060225732 | Djupesland | Oct 2006 | A1 |
20060231094 | Djupesland | Oct 2006 | A1 |
20070039614 | Djupesland | Feb 2007 | A1 |
20070125371 | Djupesland | Jun 2007 | A1 |
20070186927 | Djupesland et al. | Aug 2007 | A1 |
20080161771 | Djupesland | Jul 2008 | A1 |
20080163874 | Djupesland | Jul 2008 | A1 |
20080221471 | Djupesland et al. | Sep 2008 | A1 |
20080223363 | Djupesland | Sep 2008 | A1 |
20080289629 | Djupesland et al. | Nov 2008 | A1 |
20090101146 | Djupesland | Apr 2009 | A1 |
20090293873 | Djupesland et al. | Dec 2009 | A1 |
20090304802 | Djupesland et al. | Dec 2009 | A1 |
20090314293 | Djupesland | Dec 2009 | A1 |
20090320832 | Djupesland | Dec 2009 | A1 |
20100035805 | Hafner | Feb 2010 | A1 |
20100051022 | Djupesland et al. | Mar 2010 | A1 |
20100057047 | Djupesland et al. | Mar 2010 | A1 |
20100242959 | Djupesland et al. | Sep 2010 | A1 |
20100282246 | Djupesland et al. | Nov 2010 | A1 |
20100288275 | Djupesland et al. | Nov 2010 | A1 |
20100300439 | Djupesland et al. | Dec 2010 | A1 |
20110023869 | Djupesland | Feb 2011 | A1 |
20110053827 | Hafner | Mar 2011 | A1 |
20110088690 | Djupesland et al. | Apr 2011 | A1 |
20110088691 | Djupesland | Apr 2011 | A1 |
20110114087 | Djupesland et al. | May 2011 | A1 |
20110126830 | Djupesland et al. | Jun 2011 | A1 |
20110259329 | Djupesland et al. | Oct 2011 | A1 |
20110318345 | Djupesland | Dec 2011 | A1 |
20120000459 | Djupesland | Jan 2012 | A1 |
20120006323 | Djupesland | Jan 2012 | A1 |
20120073571 | Djupesland | Mar 2012 | A1 |
20120090608 | Djupesland et al. | Apr 2012 | A1 |
20120260915 | Djupesland | Oct 2012 | A1 |
20130098362 | Djupesland et al. | Apr 2013 | A1 |
20130125889 | Djupesland et al. | May 2013 | A1 |
20130327320 | Djupesland | Dec 2013 | A1 |
20140018295 | Djupesland | Jan 2014 | A1 |
20140041660 | Djupesland et al. | Feb 2014 | A1 |
20140060536 | Djupesland | Mar 2014 | A1 |
20140073562 | Djupesland | Mar 2014 | A1 |
20140144442 | Djupesland et al. | May 2014 | A1 |
20140144443 | Djupesland et al. | May 2014 | A1 |
20140166008 | Djupesland | Jun 2014 | A1 |
20140202456 | Djupesland | Jul 2014 | A1 |
20140246022 | Djupesland et al. | Sep 2014 | A1 |
20150007811 | Djupesland et al. | Jan 2015 | A1 |
20150013670 | Djupesland et al. | Jan 2015 | A1 |
20150013677 | Djupesland et al. | Jan 2015 | A1 |
20150053201 | Djupesland et al. | Feb 2015 | A1 |
20150090259 | Djupesland et al. | Apr 2015 | A1 |
20150101605 | Djupesland et al. | Apr 2015 | A1 |
20150144129 | Djupesland et al. | May 2015 | A1 |
20150165139 | Hafner | Jun 2015 | A1 |
20150182709 | Djupesland | Jul 2015 | A1 |
20150246194 | Djupesland et al. | Sep 2015 | A1 |
20150367090 | Djupesland et al. | Dec 2015 | A1 |
20150367091 | Djupesland et al. | Dec 2015 | A1 |
20160001022 | Djupesland et al. | Jan 2016 | A1 |
20160045687 | Djupesland | Feb 2016 | A1 |
20160051778 | Djupesland et al. | Feb 2016 | A1 |
20160074603 | Djupesland et al. | Mar 2016 | A1 |
20160082206 | Djupesland et al. | Mar 2016 | A1 |
20160082207 | Djupesland et al. | Mar 2016 | A1 |
Number | Date | Country |
---|---|---|
200994915 | Dec 2007 | CN |
101918061 | Dec 2010 | CN |
2471973 | Jan 2011 | GB |
2010540147 | Dec 2010 | JP |
2010117362 | Nov 2011 | RU |
WO 9622802 | Aug 1996 | WO |
WO 9853869 | Dec 1998 | WO |
WO 0051672 | Sep 2000 | WO |
WO 0178818 | Oct 2001 | WO |
WO 0197689 | Dec 2001 | WO |
WO 02068029 | Sep 2002 | WO |
WO 02068030 | Sep 2002 | WO |
WO 02068031 | Sep 2002 | WO |
WO 02068032 | Sep 2002 | WO |
WO 03000310 | Jan 2003 | WO |
WO 03020350 | Mar 2003 | WO |
WO 03082393 | Oct 2003 | WO |
WO 03084591 | Oct 2003 | WO |
WO 03090812 | Nov 2003 | WO |
WO 2004004814 | Jan 2004 | WO |
WO 2004004922 | Jan 2004 | WO |
WO 2004060433 | Jul 2004 | WO |
WO 2004103447 | Dec 2004 | WO |
WO 2005016423 | Feb 2005 | WO |
WO 2005021059 | Mar 2005 | WO |
WO 2006030210 | Mar 2006 | WO |
WO 2006090149 | Aug 2006 | WO |
WO 2007083073 | Jul 2007 | WO |
WO 2007093784 | Aug 2007 | WO |
WO 2007093791 | Aug 2007 | WO |
WO 2007099361 | Sep 2007 | WO |
WO 2007102089 | Sep 2007 | WO |
WO 2007107887 | Sep 2007 | WO |
WO 2007125318 | Nov 2007 | WO |
WO 2007141541 | Dec 2007 | WO |
WO 2008012531 | Jan 2008 | WO |
WO 2008065403 | Jun 2008 | WO |
WO 2008067254 | Jun 2008 | WO |
WO 2008081326 | Jul 2008 | WO |
WO 2008081327 | Jul 2008 | WO |
WO 2008122018 | Oct 2008 | WO |
WO 2008122791 | Oct 2008 | WO |
WO 2008122795 | Oct 2008 | WO |
WO 2009044172 | Apr 2009 | WO |
WO2009044172 | Apr 2009 | WO |
WO 2010029441 | Mar 2010 | WO |
WO 2011153406 | Dec 2011 | WO |
WO 2012035427 | Mar 2012 | WO |
WO 2012123819 | Sep 2012 | WO |
WO 2013124491 | Aug 2013 | WO |
WO 2013124492 | Aug 2013 | WO |
WO 2013124493 | Aug 2013 | WO |
WO 2014155192 | Oct 2014 | WO |
Entry |
---|
Cindy H. Dubin, Nothing to Sneeze At, Pharmaceutical Formulation & Quality Magazine (Jan. 29, 2003). |
Per Gisle Djupesland, Nasal Delivery of Vaccines, EPC (Jan. 29, 2003). |
Per Gisle Djupesland, Who Nose How Far Nasal Delivery Can Go?, EPC (Oct. 7, 2003). |
Per Gisle Djupesland, Bi-directional Nasal Drug Delivery, Innovations in Pharmaceutical Technology (Jul. 10, 2004). |
P.G. Djupesland, Bi-Directional Nasal Delivery of Aerosols Can Prevent Lung Deposition, Journal of Aerosol Medicine (Sep. 2004). |
Bi-Directional Nasal Device Delivers Drug on Exhalation, Pharmaceutical Technology (Sep. 10, 2004). |
Ola Dale et al., Intranasal Midazolam: A Comparison of Two Delivery Devices in Human Volunteers, Journal of Pharmacy and Pharmacology (Oct. 2004). |
M. Kleven, Using Computational Fluid Dynamics (CFD) to Improve the Bi-Directional Nasal Drug Delivery Concept, Trans IChemE Part C. (Jun. 2005). |
Per Gisle Djupesland, Breath-Actuated Bi-Directional Delivery Sets the Nasal Market on a New Course, ONdrugDelivery (Oct. 10, 2005). |
Hilde Bakke et al., Oral Spray Immunization May be an Alternative to Intranasal Vaccine Delivery to Induce Systemic Antibodies But Not Nasal Mucosal or Cellular Immunity, Scan J. of Immunol. (Mar. 2006). |
P.G. Djupesland et al., Breath Actuated Nasal Device Improves Delivery to Target Sites Beyond the Nasal Valve, The Laryngoscope (Mar. 2006). |
R. Luthringer et al., Rapid Absorption of Sumatriptan Powder and Effects on Glyceryl tinitrate Model of Headache Following Intranasal Delivery Using a Novel Bi-Directional Device, Journal of Pharmacy and Pharmacology (Jan. 2009). |
A. Skretting et al., A New Method for Scintigraphic Quantification of Deposition and Clearance in Anatomical Regions of the Human Nose, Nuclear Medicine Communications (Aug. 2009). |
Vlckovia et al., Effective Treatment of Mild-to-Moderate Nasal Polyposis with Fluticasone Delivered by a Novel Device, Rhinology (Oct. 22, 2009). |
Per Gisle Djupesland et al., Impact of Baseline Nasal Polyp Size and Previous Surgery on Efficacy of Fluticasone Delivered With a Novel Device: A Subgroup Analysis, Am. J. Rhinology Allergy (2010). |
P.G. Djupesland et al., Intranasal Sumatriptan Powder Delivered by a Novel Breath Actuated Bi-Directional Device for the Acute Treatment of Migraine: A Randomised Placebo-Controlled Study, Cephalalgia (Mar. 17, 2010). |
F.S. Hansen et al., Preliminary Efficacy of Fluticasone Delivered by a Novel Device in Recalcitrant Chronic Rhinosinusitis, Rhinology (Jun. 26, 2010). |
Per Gisle Djupesland, Nasal Drug Delivery Devices: Characteristics and Performance in Clinical Perspective—A Review, Drug. Deliv. and Transl. Res. (Oct. 18, 2012). |
Per Gisle Djupesland, Nasal Deposition and Clearance in Man: Comparison of a Bidirectional Powder Device and a Traditional Liquid Spray Pump, Journal of Aerosol Medicine and Pulmonary Drug Delivery (Nov. 2012). |
Stewart J. Tepper, Clinical Implications for Breath-Powered Powder Sumatriptan Intranasal Treatment, Headache, The American Headache Society (Apr. 29, 2013). |
Mohammad Obaidi et al., Improved Pharmacokinetics of Sumatriptan With Breath Powered Nasal Delivery of Sumatriptan Powder, Headache, The American Headache Society (May 24, 2013). |
Per Gisle Djupesland, Breath Powdered Nasal Delivery: A New Route to Rapid Headache Relief, Headache, The American Headache Society (Jun. 4, 2013). |
Per Gisle Djupesland et al., The Nasal Approach to Delivering Treatment for Brain Diseases: An Anatomic, Physiologic, and Delivery Technology Overview, Therapeutic Delivery (2014). |
R.K. Cady et al., A Randomized Double-Blind, Placebo Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study), Headache (Sep. 8, 2014). |
S.J. Tepper et al., AVP-825 Breath-Powdered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs. 100 mg Oral Sumatripta in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks, Headache: The Journal of Head and Face Pain (Mar. 29, 2015). |
D. S. Quintana et al., Low-dose Oxytocin Delivered Intranasally with Breath Powdered Device Affects Social-Cognitive Behavior: A Randomized Four-Way Crossover Trial with Nasal Cavity Dimension Assessment, Transl Psychiatry (Jul. 14, 2015). |
R. Mahmoud, Breathe Out, Innovations in Phar, Tech. (Dec. 10, 2015). |
Number | Date | Country | |
---|---|---|---|
20150246194 A1 | Sep 2015 | US |
Number | Date | Country | |
---|---|---|---|
61603089 | Feb 2012 | US |